CytoDyn reports 86% median ctDNA reduction at week 2 in Phase 2 colorectal cancer trial
CYDY•CytoDyn reported an 86% median reduction in ctDNA at week 2 in its Phase 2 CLOVER trial in metastatic colorectal cancer. The study enrolled 66 patients, and the combination of leronlimab, trifluridine/tipiracil and bevacizumab produced deeper blood-based tumor DNA reductions than regimens without leronlimab.
1. CLOVER trial results
CytoDyn presented updated Phase 2 CLOVER results at ESMO in Madrid on Oct. 25, 2026. The study enrolled 66 patients at seven sites between June 2025 and May 2026.
2. Treatment and safety
Patients received leronlimab with trifluridine/tipiracil and bevacizumab. Available safety data showed no leronlimab-related treatment discontinuations, serious toxicities limiting dosing or adverse events above moderate severity.
